Where does Luke Evnin work?

Luke Evnin is Co-founder, Board member (Chairman) of Werewolf Therapeutics and Advisor at MPM BioImpact and Board director at Umoja Biopharma, Inc. and Board director at Frontier Medicines.

What companies did Luke Evnin found?

Luke Evnin founded Werewolf Therapeutics.

What boards does Luke Evnin sit on?

Luke Evnin holds tracked board seats at Amphivena Therapeutics, Blade Therapeutics, Frontier Medicines, Harpoon Therapeutics, Maverick Therapeutics, Oncorus, Potenza Therapeutics, Redona Therapeutics, Inc., Trieza Therapeutics, Umoja Biopharma, Inc..

Where did Luke Evnin go to school?

Luke Evnin studied at University of California, San Francisco (PhD, BioChemistry); Princeton University (Bachelor’s Degree, Molecular Biology).

Luke Evnin

InvestorFounder

Advisor at MPM BioImpact · Board director at Umoja Biopharma, Inc. · Board director at Frontier Medicines · Co-founder, Board member (Chairman) at Werewolf Therapeutics

California

FoundedWerewolf Therapeutics

About

Co-founder of the predecessor company MPM Capital in 1997 and Advisor to the firm. Served as interim CEO of publicly traded Werewolf Therapeutics and co-founded seven MPM portfolio companies including Blade Therapeutics, Harpoon Therapeutics, and Tizona Therapeutics over a 30+ year venture capital career.

Board director at Umoja Biopharma, Inc.

Intro paths

→

In turn, Luke can intro founders to Umoja Biopharma, Inc.'s investors below.

Umoja Biopharma, Inc.'s investors · 7

DCVC (Data Collective)Palo Alto · $5M – $25M checks · since 2021 DCVC BioPalo Alto · since 2021 K2 HealthVenturesBoston · $10M – $100M checks · since 2021 MPM BioImpactBoston · $1M – $15M checks · since 2021 Qiming Venture Partners USACambridge · since 2021 SoftBank GroupTokyo · since 2021 SoftBank Vision FundLondon · since 2021

Co-founders at Umoja Biopharma, Inc.

Andrew M. ScharenbergExecutive Officer, Director

Board director at Frontier Medicines

Intro paths

→

In turn, Luke can intro founders to Frontier Medicines's investors below.

Frontier Medicines's investors · 7

Berkeley CatalystBerkeley · since 2021 DCVC (Data Collective)Palo Alto · $5M – $25M checks · since 2021 DCVC BioPalo Alto · since 2025 Deerfield Management CompanyNew York · since 2025 Droia VenturesLeuven · $540K checks · since 2021 MPM BioImpactBoston · $1M – $15M checks · since 2021 RA CapitalBoston · since 2021

Co-founders at Frontier Medicines

Chris Varma, Ph.D.Executive Officer, Director

Chris VarmaCo-founder, Chairman and CEO

Co-founder, Board member (Chairman) at Werewolf Therapeutics

Intro paths

→

In turn, Luke can intro founders to Werewolf Therapeutics's investors below.

Werewolf Therapeutics's investors · 6

DC Investment PartnersMcLean · $10M checks · since 2020 K2 HealthVenturesBoston · $10M – $100M checks · since 2020 Longwood FundBoston · since 2020 MPM BioImpactBoston · $1M – $15M checks · since 2020 RA CapitalBoston · since 2020 Taiho Ventures, LLCMenlo Park · since 2020

Co-founders at Werewolf Therapeutics

Daniel J. HicklinFounder, President, Chief Executive Officer, and Board member

Daniel HicklinExecutive Officer, Director

Experience

Vie VenturesCo-Founder; Managing Directorcurrent2025 — presentCambridge, MA
Scleroderma Research FoundationChairpersoncurrent1999 — present
Annulus CellarsProprietorcurrent2020 — presentNapa Valley, CA
Werewolf TherapeuticsChairpersoncurrent2016 — presentCambridge, MA
MPM CapitalCo-Founder; Senior Advisorcurrent1997 — present
Accel PartnersGeneral Partner1990 — 1997

Deals · 9

Redona Therapeutics, Inc.Board seat

via MPM BioImpact · filed Jul 2023 · $76.9M raise

Blade TherapeuticsBoard seat

via MPM BioImpact · filed Oct 2019 · $50M raise

Harpoon TherapeuticsBoard seat

via MPM BioImpact · filed Nov 2018 · $70M raise

OncorusBoard seat

via MPM BioImpact · filed Sep 2018 · $61.4M raise

Amphivena TherapeuticsBoard seat

via MPM BioImpact · filed Jun 2017 · $19.5M raise

Maverick TherapeuticsBoard seat

via MPM BioImpact · filed Jan 2017 · $56M raise

Trieza TherapeuticsBoard seat

via MPM BioImpact · filed Dec 2016 · $1 raise

Potenza TherapeuticsBoard seat

via MPM BioImpact · filed Mar 2016 · $38M raise

Vesuvius PharmaceuticalsBoard seat

via MPM BioImpact · filed Jan 2015 · $33M raise

Attribution from SEC filings, press coverage, and firm rosters.

Other disclosed investments

Board seats

Frontier Medicines Umoja Biopharma, Inc.Werewolf Therapeutics

Per SEC Form D filings.

Colleagues at MPM BioImpact

Andrew Scharenberg

Entrepreneur Partner at MPM BioImpact

Ansbert Gadicke, M.D.

Chairman at MPM BioImpact

Ansbert K. Gadicke

Managing Partner at MPM BioImpact

Aparna Parikh

Entrepreneur Partner at MPM BioImpact

Bard Geesaman

Managing Partner at MPM Capital

Binsen Li

Principal at MPM BioImpact

Brendan Furey

Chief Compliance Officer at MPM BioImpact

Brian Shuster

Entrepreneur Partner at MPM BioImpact

Frequently asked questions

Who is Luke Evnin?: Co-founder of the predecessor company MPM Capital in 1997 and Advisor to the firm. Served as interim CEO of publicly traded Werewolf Therapeutics and co-founded seven MPM portfolio companies including Blade Therapeutics, Harpoon Therapeutics, and Tizona Therapeutics over a 30+ year venture capital career.
Where does Luke Evnin work?: Luke Evnin is Co-founder, Board member (Chairman) of Werewolf Therapeutics and Advisor at MPM BioImpact and Board director at Umoja Biopharma, Inc. and Board director at Frontier Medicines.
What companies did Luke Evnin found?: Luke Evnin founded Werewolf Therapeutics.
What boards does Luke Evnin sit on?: Luke Evnin holds tracked board seats at Amphivena Therapeutics, Blade Therapeutics, Frontier Medicines, Harpoon Therapeutics, Maverick Therapeutics, Oncorus, Potenza Therapeutics, Redona Therapeutics, Inc., Trieza Therapeutics, Umoja Biopharma, Inc..
Where did Luke Evnin go to school?: Luke Evnin studied at University of California, San Francisco (PhD, BioChemistry); Princeton University (Bachelor’s Degree, Molecular Biology).